Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Open accessThe DOI matches its Crossref record; 200 of the 200 references it cites were found in a registry or an index.
Abstract
Treatment options for retinal diseases, such as neovascular age-related macular degeneration, diabetic retinopathy, and retinal vascular disorders, have markedly expanded following the development of anti-vascular endothelial growth factor intravitreal injection methods. However, because intravitreal treatment requires monthly or bimonthly repeat injections to achieve optimal efficacy, recent investigations have focused on extended drug delivery systems to lengthen the treatment intervals in the long term. Dose escalation and increasing molecular weight of drugs, intravitreal implants and nanoparticles, hydrogels, combined systems, and port delivery systems are presently under preclinical and clinical investigations. In addition, less invasive techniques rather than intravitreal administration routes, such as topical, subconjunctival, suprachoroidal, subretinal, and trans-scleral, have been evaluated to reduce the treatment burden. Despite the latest advancements in the field of ophthalmic pharmacology, enhancing drug efficacy with high ocular bioavailability while avoiding systemic and local adverse effects is quite challenging. Consequently, despite the performance of numerous in vitro studies, only a few techniques have translated to clinical trials. This review discusses the recent developments in ocular drug delivery to the retina, the pharmacokinetics of intravitreal drugs, efforts to extend drug efficacy in the intraocular space, minimally invasive techniques for drug delivery to the retina, and future perspectives in this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Biodegradable and non-biodegradable ocular implants have been used in several drug treatments for conditions such as diabetic macular edema and posterior uveitis, among others, and provide a method for sustained release of poorly soluble steroids.118,126”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [126]
Experimental — accuracy not yet measuredIn the citing paper
“In the field of ophthalmology, different routes of administration, such as subconjunctival, intravitreal, suprachoroidal and subretinal injections, are commonly used to treat various diseases61.”
From An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species (2024) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Hyaluronic Acid Hydrogels for Biomedical Applications
Burdick, J. A., & Prestwich, G. D. (2011) · Advanced Materials · doi:10.1002/adma.201003963 · Cited by 2,139
Structure and design of polymeric surfactant-based drug delivery systems
Torchilin, V. P. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00299-1 · Cited by 1,822 · cited 2×
“Micelles are nanosized amphiphilic core-shell (hydrophobic core, hydrophilic shell) carriers with polymeric surfactants [91,92].”
BackgroundPolymer nanoparticles: Preparation techniques and size-control parameters
Rao, J. P., & Geckeler, K. E. (2011) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2011.01.001 · Cited by 1,725 · cited 2×
“observed significant suppression of neovascularization [98].”
MethodDendrimer biocompatibility and toxicity
DUNCAN, R., & IZZO, L. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.019 · Cited by 1,158 · cited 1×
“Dendrimers are synthetic three-dimensional repeating-unit branched macromolecules; polyamidoamine (PAMAM) and DAB polypropyleneimine (PPI/DAB) are widely used dendrimers for biomedical purposes [79,80].”
BackgroundRanibizumab for Macular Edema following Central Retinal Vein Occlusion
Brown, D. M., Campochiaro, P. A., Singh, R. P., Li, Z., Gray, S., Saroj, N., Rundle, A. C., Rubio, R. G., & Murahashi, W. Y. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.022 · Cited by 1,155
Hydrogels for Protein Delivery
Vermonden, T., Censi, R., & Hennink, W. E. (2012) · Chemical Reviews · doi:10.1021/cr200157d · Cited by 1,091
Amphiphilic block copolymers for drug delivery
Adams, M. L., Lavasanifar, A., & Kwon, G. S. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10397 · Cited by 1,078
Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects
Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., & Alcudia, A. (2020) · Nanomaterials · doi:10.3390/nano10071403 · Cited by 1,061
Cited by
Han, H., Li, S., Xu, M., Zhong, Y., Fan, W., Xu, J., Zhou, T., Ji, J., Ye, J., & Yao, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114770 · Cited by 322
Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications
Zhang, J., Zhang, J., Zhang, C., Zhang, J., Gu, L., Luo, D., & Qiu, Q. (2022) · Cells · doi:10.3390/cells11213362 · Cited by 300
“When delivered to the suprachoroidal space, the drug can target both the retina and the choroid, overcoming multiple ocular tissue barriers and achieving the efficacy at low dose [142,214].”
BackgroundHyaluronic acid in ocular drug delivery
Zhang, X., Wei, D., Xu, Y., & Zhu, Q. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118006 · Cited by 196
Considerations for Polymers Used in Ocular Drug Delivery
Allyn, M. M., Luo, R. H., Hellwarth, E. B., & Swindle-Reilly, K. E. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.787644 · Cited by 159
Strategies for non-viral vectors targeting organs beyond the liver
Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A., & Sahay, G. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01563-4 · Cited by 173
“Lastly, suprachoroidal administration employs microneedles or microcannulas for trans-scleral delivery to the suprachoroidal space, accessing the choroid, RPE and neural retina with high bioavailability and specificity 47 .”
InfluentialGene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Cellulosic Polymers for Enhancing Drug Bioavailability in Ocular Drug Delivery Systems
Gupta, B., Mishra, V., Gharat, S., Momin, M. M., & Omri, A. (2021) · Pharmaceuticals · doi:10.3390/ph14111201 · Cited by 156
Polymer-Based Nanosystems—A Versatile Delivery Approach
Niculescu, A.-G., & Grumezescu, A. M. (2021) · Materials · doi:10.3390/ma14226812 · Cited by 90
Abdellatif, A. A. H., Mohammed, H. A., Khan, R. A., Singh, V., Bouazzaoui, A., Yusuf, M., Akhtar, N., Khan, M., Al-Subaiyel, A., Mohammed, S. A. A., et al. (2021) · Nanotechnology Reviews · doi:10.1515/ntrev-2021-0096 · Cited by 84
Lipid nanoparticles for the posterior eye segment
Bonilla, L., Espina, M., Severino, P., Cano, A., Ettcheto, M., Camins, A., García, M. L., Souto, E. B., & Sánchez-López, E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010090 · Cited by 76
Afarid, M., Mahmoodi, S., & Baghban, R. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01567-7 · Cited by 76
The Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery
Ranade, S. V., Wieland, M. R., Tam, T., Rea, J. C., Horvath, J., Hieb, A. R., Jia, W., Grace, L., Barteselli, G., & Stewart, J. M. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2069301 · Cited by 75
“The requirement for frequent injections of anti-VEGF therapy reflects the short intraocular half-life of these biologic agents, and the development of long-acting ocular drug delivery strategies has proved difficult (reviewed in Kim and Woo (2021)).”
BackgroundInfluentialPandit, J., Sultana, Y., & Aqil, M. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118217 · Cited by 70
Drug delivery via the suprachoroidal space for the treatment of retinal diseases
Naftali Ben Haim, L., & Moisseiev, E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13070967 · Cited by 68
“Subretinal injections are very targeted, yet require an invasive surgical procedure, that also carries significant risks [5].”
BackgroundMicroneedle-based ocular drug delivery systems – recent advances and challenges
Gadziński, P., Froelich, A., Wojtyłko, M., Białek, A., Krysztofiak, J., & Osmałek, T. Z. (2022) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.13.98 · Cited by 73
Roy, G., Garg, P., & Venuganti, V. V. K. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121305 · Cited by 65
Microemulsion Based Nanostructures for Drug Delivery
Arredondo-Ochoa, T., & Silva-Martínez, G. A. (2022) · Frontiers in Nanotechnology · doi:10.3389/fnano.2021.753947 · Cited by 59
“Topical ocular drop delivery is an efficient administration route for the treatment of anterior segment illness but inefficient to treat posterior segment of the eye since multiple ocular barriers make it inefficient to drug delivering (Rodrigues et al., 2018; Kim and Woo, 2021).”
BackgroundOcular Delivery of Therapeutic Proteins: A Review
Shastri, D. H., Silva, A. C., & Almeida, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010205 · Cited by 60
Gu, H., Chen, P., Liu, X., Lian, Y., Xi, J., Li, J., Song, J., & Li, X. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126480 · Cited by 54
Research progress of exosomes in pathogenesis, diagnosis, and treatment of ocular diseases
Feng, X., Peng, Z., Yuan, L., Jin, M., Hu, H., Peng, X., Wang, Y., Zhang, C., Luo, Z., & Liao, H. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1100310 · Cited by 52
“Although intravitreal injection of anti VEGF is an effective treatment, subconjunctival injection is less invasive than intravitreal injection (Kim and Woo, 2021).”
BackgroundPenetrating-peptide-mediated non-invasive Axitinib delivery for anti-neovascularisation
Huang, Y., Zhu, Y., Cai, D., Guo, Q., Wang, J., Lei, L., Li, X., & Shi, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.009 · Cited by 46
Ocular barriers as a double-edged sword: preventing and facilitating drug delivery to the retina
Wang, L., & Zhang, H. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01231-5 · Cited by 44
The Emerging Role of Topical Ocular Drugs to Target the Posterior Eye
Wang, L., Zhou, M., & Zhang, H. (2021) · Ophthalmology and Therapy · doi:10.1007/s40123-021-00365-y · Cited by 43
Rafael, D. F. D. S., Guerrero, M., Maricán, A., Arango, D., Sarmento, B. F. C. C., Ferrer, R., Durán‐Lara, E. F., Clark, S. J., & Schwartz, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051484 · Cited by 41
An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species
Luo, S., Jiang, H., Li, Q., Qin, Y., Yang, S., Li, J., Xu, L., Gou, Y., Zhang, Y., Liu, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48221-4 · Cited by 39
“In the fi eld of ophthalmology, different routes of administration, such as subconjunctival, intravitreal, suprachoroidal and subretinal injections, are commonly used to treat various diseases 61 .”
Yang, R., Tang, S., Xie, X., Jin, C., Tong, Y., Huang, W., & Zan, X. (2024) · Advanced Materials · doi:10.1002/adma.202314126 · Cited by 42
Hashida, N., & Nishida, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114870 · Cited by 38
Veritti, D., Sarao, V., Bin, F. D., & Lanzetta, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051416 · Cited by 37
Deferasirox nanosuspension loaded dissolving microneedles for ocular drug delivery
Faizi, H. S., Nasiri, M. I., Wu, Y., Mishra, D., Donnelly, R. F., Minhas, M. U., Vora, L. K., & Thakur, R. R. S. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124614 · Cited by 38
Zaszczyńska, A., Niemczyk-Soczynska, B., & Sajkiewicz, P. (2022) · Polymers · doi:10.3390/polym14235278 · Cited by 38
Ottonelli, I., Bighinati, A., Adani, E., Loll, F., Caraffi, R., Vandelli, M. A., Boury, F., Tosi, G., Duskey, J. T., Marigo, V., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010025 · Cited by 36
“Non-specific diffusion through the eye can lead to poor accumulation in the retina and, finally, free drugs often suffer short half-lives and poor biodistribution through the vitreous when attempting to deliver them to the retina [10,11].”
BackgroundAshique, S., Mishra, N., Mohanto, S., Gowda, B. H. J., Kumar, S., Raikar, A. S., Masand, P., Garg, A., Goswami, P. K., & Kahwa, I. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23810 · Cited by 39
“Another crucial element of ocular medication administration is increasing drug solubility [18].”
BackgroundRetractedAnti-VEGF Drugs Dynamics: Relevance for Clinical Practice
Veritti, D., Sarao, V., Gorni, G., & Lanzetta, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020265 · Cited by 39
Su, Y., Fan, X., & Pang, Y. (2023) · Biomaterials Science · doi:10.1039/d3bm00505d · Cited by 33
Implantable sustained-release drug delivery systems: a revolution for ocular therapeutics
Cong, Y.-Y., Fan, B., Zhang, Z.-Y., & Li, G. (2023) · International Ophthalmology · doi:10.1007/s10792-023-02637-x · Cited by 33
Yu, J., Yin, Y., Leng, Y., Zhang, J., Wang, C., Chen, Y., Li, X., Wang, X., Liu, H., Liao, Y., et al. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114842 · Cited by 31
Dubashynskaya, N. V., Bokatyi, A. N., Головкин, А. С., Kudryavtsev, I. V., Serebryakova, M. K., Trulioff, A. S., Dubrovskii, Y. A., & Skorik, Y. А. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010960 · Cited by 31
“For this reason, an intravitreal dosage form must have a prolonged release profile of active pharmaceutical substances over several months while still maintaining the drug concentration at an adequate therapeutic level [8,11,12].”
BackgroundTrends in Formulation Approaches for Sustained Drug Delivery to the Posterior Segment of the Eye
Biswas, A., Choudhury, A. D., Bisen, A. C., Agrawal, S., Sanap, S. N., Verma, S. K., Mishra, A., Kumar, S., & Bhatta, R. S. (2023) · AAPS PharmSciTech · doi:10.1208/s12249-023-02673-x · Cited by 32
“In this review, we explore the different types of drug delivery options at the posterior segment of the eye with recent advancements in the controlled release of drugs through drug delivery systems.”
Mathematical Models of Ocular Drug Delivery
Sadeghi, A., Subrizi, A., del Amo, E. M., & Urtti, A. O. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.11.28 · Cited by 30
Bohley, M., Dillinger, A. E., Tamm, E. R., & Göpferich, A. M. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.05.024 · Cited by 29
Moon, C., Lee, A.-J., Jeon, H., Kim, E.-B., & Ha, K. (2023) · Theranostics · doi:10.7150/thno.81714 · Cited by 29
“Anti-DR drugs such as anti-VEGF agents and corticosteroids have beneficial effects on retinal neovascularization; however, they do not produce satisfactory outcomes in all patients and can cause side effects due to their requirement for frequent intravitreal administration to maintain therapeutic intraocular drug leve…”
Intravitreal injectable hydrogel rods with long-acting bevacizumab delivery to the retina
Lee, S., Hong, H. K., Song, J. S., Jeong, S. I., Chung, J., Woo, S. J., & Park, K. D. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.09.025 · Cited by 28
Self-citationBiodegradable and removable implants for controlled drug delivery and release application
Chavda, V. P., Jogi, G., Paiva‐Santos, A. C., & Kaushik, A. K. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2110065 · Cited by 29
“Dexamethasone (Ozurdex) ● PLGA-based intravitreal implants prepared by modified injection technique ● Efficacy for 3– 6 months ● Implant degradation by itself in the vitreous cavity [28]”
MethodNanoparticles for the treatment of glaucoma-associated neuroinflammation
Lambuk, L., Suhaimi, N. A. A., Sadikan, M. Z., Jafri, A. J. A., Ahmad, S., Nasir, N. A. A., Uskoković, V., Kadir, R., & Mohamud, R. (2022) · Eye and Vision · doi:10.1186/s40662-022-00298-y · Cited by 28
“Polymer-based NPs Polymeric NPs have played a major role in the advancement of NP-mediated drug delivery, given that they have proven successful for alleviating numerous diseases [155].”
BackgroundInfluentialGhezzi, M., Ferraboschi, I., Fantini, A., Pescina, S., Padula, C., Santi, P., Sissa, C., & Nicoli, S. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122911 · Cited by 27
Santonocito, M., Zappulla, C., Viola, S., Rosa, L. R. L., Solfato, E., Abbate, I., Tarallo, V., Apicella, I., Platania, C. B. M., Maugeri, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094404 · Cited by 27
Polymer-free hydrogel made of lipid nanocapsules, as a local drug delivery platform
Pitorre, M., Gazaille, C., Pham, L. T. T., Frankova, K., Bejaud, J., Lautram, N., Riou, J., Perrot, R., Geneviève, F., Moal, V., et al. (2021) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.112188 · Cited by 27
Basavarajappa, D. K., Gupta, V., Chitranshi, N., Wall, R. V., Rajput, R., Pushpitha, K., Sharma, S., Mirzaei, M., Klistorner, A. I., & Graham, S. L. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.344952 · Cited by 27
“Various novel drug delivery strategies such as emulsions, liposomes, nanomicelles, and nanoparticles have been developed to surpass these barriers and enhance drug levels in tissues (Amadio et al., 2016; Kang-Mieler et al., 2020; Kim and Woo, 2021).”
BackgroundTsai, C.-H., Hoang, L. N., Lin, C. C., Pan, L.-C., Wu, C.-L., Lin, I., Wang, P., & Tseng, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061253 · Cited by 26
Zhuang, A., Chai, P., Wang, S., Zuo, S., Yu, J., Jia, S., Ge, S., Jia, R., Zhou, Y., Shi, W., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.660 · Cited by 26
“22 25 In addition, numerous mechanisms underlying metformin-induced tumour inhibition have been discovered.”
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“…homeostasis in the eye following AAV-mediated retinal gene therapy. eluting implants, hydrogels, and micro-or nanoparticle delivery systems that can achieve therapeutic concentrations in the posterior segment for several months (Lance et al., 2015; Kim and Woo, 2021) following AAV gene therapy.”
Complex in vitro models positioned for impact to drug testing in pharma: a review
Kang, S., Chen, E. C., Cifuentes, H., Co, J. Y., Cole, G., Graham, J. C., Hsia, I., Kiyota, T., Klein, J. A., Kroll, K. T., et al. (2024) · Biofabrication · doi:10.1088/1758-5090/ad6933 · Cited by 25
“Combined with the limited regenerative potential of the retinal, this has spurred development of in vitro retinal models as a predictive tool (figure 11) for identifying retinal toxicities [314], modeling drug efficacy [315], and studying delivery of molecules through the eye [316].”
Rykowska, I., Nowak, I., Nowak, R., & Michałkiewicz, O. (2025) · Molecules · doi:10.3390/molecules30122542 · Cited by 25
How to Fabricate Hyaluronic Acid for Ocular Drug Delivery
Kim, M., Jung, M.-Y., Lee, D., Ahn, S., Lee, G. M., & Park, C. Y. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121604 · Cited by 23
“Currently, anti-VEGF drug implants for long-term use are actively being developed [78].”
InfluentialBiomaterial Drug Delivery Systems for Prominent Ocular Diseases
Sapowadia, A., Ghanbariamin, D., Zhou, L., Zhou, Q., Schmidt, T. A., Tamayol, A., & Chen, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071959 · Cited by 23
“Periocular administration of drugs is also known as a successful approach for treating ocular diseases; however, there are still some drawbacks of using this route that limit efficient drug delivery, such as an increase in intraocular pressure or drug elimination by choroidal circulation [8,15,16].”
BackgroundTopical Treatment for Retinal Degenerative Pathologies: A Systematic Review
Samoilă, L., Voștinaru, O., Dinte, E., Bodoki, A., Iacob, B., Bodoki, E., & Samoilă, O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098045 · Cited by 20
Long‐Acting Ocular Injectables: Are We Looking In The Right Direction?
Dang, M., & Shoichet, M. S. (2023) · Advanced Science · doi:10.1002/advs.202306463 · Cited by 18
Torkashvand, A., Izadian, A., & Hajrasouliha, A. R. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.07.002 · Cited by 19
Cooper, R. C., Wang, J., & Yang, H. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c00597 · Cited by 17
Valachová, K., Hassan, M. E., Tamer, T. M., & Šoltés, L. (2025) · Molecules · doi:10.3390/molecules30193883 · Cited by 17
“Additionally, long-term anti-VEGF drug implants have been designed [119].”
Farkas, E., Abboud, H. A., Nagy, N., Hofmeister, B., Ostorházi, E., Tóth, B. D., Pinke, B. G., Mészáros, L., Zelkó, R., & Kazsoki, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179228 · Cited by 16
Update on current pharmacologic therapies for diabetic retinopathy
Muns, S. M., Villegas, V. M., Flynn, H. W., & Schwartz, S. G. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2230139 · Cited by 16
Microbubble-Assisted Ultrasound for Drug Delivery to the Retina in an Ex Vivo Eye Model
Rousou, C., van Kronenburg, N. C. H., Sonnen, A. F. ‐., van Dijk, M. R., MOONEN, C. T. W., Storm, G., Mastrobattista, E., & Deckers, R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041220 · Cited by 15
Retinal Diseases: The Next Frontier in Pharmacodelivery
Ben-Arzi, A., Ehrlich, R., & Neumann, R. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050904 · Cited by 15
“, improved eye drops, injections to the subconjunctival, suprachoroidal and subretinal space, trans-scleral port delivery systems, and intravitreal injections (as seen in Figure 2) [22].”
BackgroundNew Prospects for Retinal Pigment Epithelium Transplantation
Gullapalli, V. K., & Zarbin, M. A. (2022) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000521 · Cited by 16
Quantitative systems pharmacology of the eye: Tools and data for ocular QSP
Kuepfer, L., Fuellen, G., & Stahnke, T. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12918 · Cited by 18
Grover, A., Sankaranarayanan, S., Mathur, V., Suri, P., Qiu, H., Andrews-Zwilling, Y. S., Mease, K. M., Taylor, L. K., Cahir-McFarland, E. D., Keswani, S. C., et al. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.2.3 · Cited by 14
“29 IVT injection of the murine parent antibody of ANX007 blocks C1q in C57BL/6 J mice and slows the progression of retinal atrophy in an oxidative model of photoreceptor cell damage.”
BackgroundIntraocular injectable hydrogels for the delivery of cells and nanoparticles
Moreno, E. I., Alonso, M. J., & Abbadessa, A. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101767 · Cited by 18
“…suggest that particles larger than 500 nm tend to be rapidly cleared from the vitreous to the aqueous humor flow, whereas smaller NPs, better if in the 200 – 250 nm range, exhibit slower clearance being able to penetrate the inner retina and offering an enhanced delivery potential [179,180].”
Ophthalmic dosage forms for drug delivery to posterior segment
Lee, J., & Rhee, Y.-S. (2022) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-021-00554-8 · Cited by 14
“Recently, the occurrence of intraocular inflammation accompanied by obstructive retinal vasculitis after the administration of brolucizumab via the intravitreal route was reported (Kim and Woo 2021).”
BackgroundAntiangiogenic therapy for ocular diseases: Current status and challenges
Chen, R., Zhu, J., Hu, J., & Li, X. (2023) · MedComm – Future Medicine · doi:10.1002/mef2.33 · Cited by 13
El-Qarra, L. H., Cosottini, N., Tangsombun, C., & Smith, D. K. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202402530 · Cited by 12
Oz, Y., Zheng, Y., Kumar, P., Kumar, L. K., Roy, A., Qi, I., Liu, Z. J., Singh, P. K., & Annabi, N. (2025) · ACS Nano · doi:10.1021/acsnano.5c02002 · Cited by 12
“− 90 While current therapeutic approaches, such as topical eye drops, and periocular or intraocular injections, remain standard, 91 they are often limited by poor retention, rapid clearance, and restricted drug bioavailability.”
Sahu, A. K., Patel, A. R., Shetty, K. H., Shah, D. O., Willcox, M. D. P., Maulvi, F. A., & Desai, D. T. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126009 · Cited by 12
Corrie, L., Kommineni, N., Kaur, J., Awasthi, A., Gundaram, R., & Kukati, L. (2023) · Current Radiopharmaceuticals · doi:10.2174/0118744710258313231105072931 · Cited by 11
Current state and potential of polymersomes as ocular drug delivery systems
Yetisgin, A. A., Sivakumar, P. M., & Çetinel, S. (2025) · Nanoscale · doi:10.1039/d5nr01273b · Cited by 11
Overcoming barriers to delivery of biologics by novel approaches and advanced delivery systems
Ahator, S. D., Franzè, S., Obuobi, S. A. O., Anderluzzi, G., Flaten, G. E., & Škalko‐Basnet, N. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115875 · Cited by 13
Vähätupa, M., Salonen, N., Uusitalo‐Järvinen, H., & Järvinen, T. A. H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111932 · Cited by 11
Advances in ophthalmic drug delivery technology for postoperative management after cataract surgery
Lee, K., Lee, G., Lee, S., & Park, C. Y. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2109624 · Cited by 13
Advancing treatment of retinal disease through in silico trials
Hernandez, R. J., Roberts, P. A., & El‐Bouri, W. K. (2023) · Progress in Biomedical Engineering · doi:10.1088/2516-1091/acc8a9 · Cited by 11
Zingale, E., Bonaccorso, A., Spadaro, A., Carbone, C., Musumeci, T., Sasmal, P. K., Doni, D. R., Jaladi, R., Amarji, B., Ramachandran, G., et al. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106026 · Cited by 10
Cimino, C., Bonilla-Vidal, L., Conti, F., Sánchez‐López, E., Bucolo, C., García, M. L., Musumeci, T., Pignatello, R., & Carbone, C. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00725 · Cited by 10
Therapeutic roles of PPARα activation in ocular ischemic diseases.
Lee, D., Tomita, Y., Negishi, K., & Kurihara, T. (2023) · PubMed · doi:10.14670/hh-18-542 · Cited by 12
Drug-Loaded Polymeric Particulated Systems for Ophthalmic Drugs Release
Mihailovici, R., Croitoriu, A., Nedeff, F., Nedeff, V., Ochiuz, L., Vasincu, D., Popa, T. O., Agop, M., Moraru, A. D., Costin, D., et al. (2022) · Molecules · doi:10.3390/molecules27144512 · Cited by 9
Intravitreal long-term sustained ranibizumab delivery using injectable microgel-embedded hydrogel
Lee, S., Park, J. Y., Hong, H. K., Son, J. Y., Kim, B., Chung, J., Woo, S. J., & Park, K. D. (2024) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2024.100947 · Cited by 9
“Various methods, including dose escalation, intravitreal implants, and port delivery systems (PDS), are currently being developed to extend treatment intervals over prolonged periods [ 5 ].”
BackgroundSelf-citationNanotechnology: A State of the Art for the Management of Ocular Disorders—A Roadmap
Ashique, S., Kumar, P., Taj, T., Debnath, B., Mukherjee, S., Patel, A., Sridhar, S. B., Panigrahy, U. P., Poonia, P., Selim, S., et al. (2025) · BioNanoScience · doi:10.1007/s12668-025-01895-6 · Cited by 10
“A ciprofloxacin cubosome-based biodegradable in situ gel was developed to improve corneal permeability and the therapeutic value of externally applied ciprofloxacin in the management of corneal ulcers and microbial keratitis [170].”
Zadeh, M. A., Alany, R. G., Satarian, L., Shavandi, A., Almousa, M. A., Brocchini, S., & Khoder, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051330 · Cited by 9
“Recently, implantable polymeric scaffolds capable of providing structural support for retinal cell growth and proliferation have gained considerable attention for retinal regenerative treatment [10].”
BackgroundLocalization of fluorescent gold nanoparticles throughout the eye after topical administration
Raîche-Marcoux, G., Méthot, S. J., Tchatchouang, A., Bettoli, C., Maranda, C., Loiseau, A., Proulx, S., Rochette, P. J., Génin, E., & Boisselier, É. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1557611 · Cited by 9
“However, scleral barriers to the choroid, combined with elimination through blood and lymphatic flow in the subconjunctival space, lead to lower bioavailability in the retina (34).”
Biali, M. E., Karch, R., Philippe, C., Haslacher, H., Tournier, N., Hacker, M., Zeitlinger, M. A., Schmidl, D., Langer, O., & Bauer, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.698966 · Cited by 8
“On the other hand, DDIs could generate therapeutic benefits by enhancing the ocular penetration of systemic treatments for retinal disorders struggling to cross the BRB, which represents so far a major challenge for ocular drug delivery (Jordán and Ruíz-Moreno, 2013; Agrahari et al., 2016; Pascual-Pasto et al., 2017;…”
BackgroundDiscovery and Potential Utility of a Novel Non-Invasive Ocular Delivery Platform
Wang, W., & Snider, N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092344 · Cited by 8
“In addition, ocular injections are usually not suitable for the delivery of small molecules as they tend to have short half-lives (usually less than 10 h) of bioavailability in the target tissues [9,14,21].”
BackgroundDeshmukh, R., Singh, R., & Mishra, S. (2023) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v41.i3.10 · Cited by 10
Diress, M., Wagle, S. R., Lim, P., Foster, T., Kovačević, B., Ionescu, C. M., Mooranian, A., & Al‐Salami, H. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2431577 · Cited by 8
Panda, P., Mohanty, S., Gouda, S. R., & Mohapatra, R. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2443144 · Cited by 11
“…preterm infantsit is one of the leading causes of childhood visual loss. in most cases, this results in permanent visual impairment or blindness [102]. laser therapy and cryotherapy have been demonstrated to be beneficial in treating ROP, although severe stages of the illness may necessitate…”
A non‐surgical method for subretinal delivery by trans‐scleral microneedle injection
Hejri, A., Chrenek, M. A., Goehring, N. T., Bowland, I. I., Noel, R. K., Yan, J., Nickerson, J. M., & Prausnitz, M. R. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10755 · Cited by 8
“…attempts to access the SRS through trans-scleral insertion using hypodermic needles have raised concerns over safety and reliability, including the risk of significant (and potentially unstoppable) choroidal hemorrhage 18,24 – 28 and retinal perforation from uncontrolled needle penetration.”
Parashar, R., Vyas, A., Sah, A. K., Hemnani, N., Thangaraju, P., & Suresh, P. K. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998240053231009060654 · Cited by 8
Diffusion of nanoparticles in heterogeneous hydrogels as vitreous humour in vitro substitutes
Lopez, M. L., Kearns, V., Curran, J. M., & Patterson, E. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-68267-0 · Cited by 8
“5, 6, 7.”
BackgroundInfluentialCimino, C., Zingale, E., Bonaccorso, A., Musumeci, T., Carbone, C., & Pignatello, R. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00554 · Cited by 7
Valente, S., Ciavarella, C., Astolfi, G., Bergantin, E., Curti, N., Buzzi, M., Fontana, L., & Versura, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810701 · Cited by 7
“In this pathway, growth factors might also be provided by blood-based products via delivery systems, beyond the injection procedures, that are actively being explored [25,26].”
BackgroundPathan, I., Raza, M. K., Roy, A., Badwaik, H. R., Sakure, K., & Uddin, A. N. M. S. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107537 · Cited by 10
Modulated approaches for strategic transportation of proteins and peptides via ocular route
Bhatt, M., & Shende, P. K. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102835 · Cited by 7
Future Perspectives for Antiangiogenic Therapy in Retinal Diseases
Budzinskaya, M. V., & Plyukhova, A. A. (2021) · Ophthalmology in Russia · doi:10.18008/1816-5095-2021-3s-638-645 · Cited by 7
Metadata
- Authors
- Kim, H. M., & Woo, S. J.
- Affiliations
- Seoul National University (KR)
- Corresponding author
- Woo, Se Joon
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2021-01-15
- Volume
- 13
- Issue
- 1
- Pages
- 108
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC7830424
- OpenAlex
- W3118619250
- Cited by
- 198
- References
- 200
- Citations by year
- 2026: 27 · 2025: 40 · 2024: 35 · 2023: 44 · 2022: 33 · 2021: 18
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation (2020R1F1A1072795, 2018M3A9B5021319)
- National Research Foundation of Korea (2020R1F1A1072795, 2018M3A9B5021319)
- Ministry of Science and ICT, South Korea (2020R1F1A1072795)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- ocular drug delivery, retinal drug delivery, intravitreal injection, intravitreal implant, nanoparticles, hydrogels, port delivery system, anti-VEGF therapy, neovascular age-related macular degeneration, diabetic retinopathy, retinal vascular disease, subconjunctival administration, ocular bioavailability, minimally invasive drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.